NRSN (NRSN) Stock Price & Analysis
NRSN (NRSN) rose 1.12% to USD 0.76 as of June 10, 2026 at 05:31 UTC, according to Nexqual real-time market data.
NRSN last closed at USD 0.75; the session ranged USD 0.75–0.82 on volume of 142,799 shares. Market capitalization is $27.44M, with a 52-week range of USD 0.63–2.6 (NCM). Source: Nexqual, June 10, 2026 at 05:31 UTC.
Key Statistics (as of June 10, 2026 at 05:31 UTC)
| Price | USD 0.76 |
|---|---|
| Change | ▲ 1.12% (up) |
| Previous Close | USD 0.75 |
| Open | USD 0.82 |
| Day Range | USD 0.75 – 0.82 |
| 52-Week Range | USD 0.63 – 2.6 |
| Volume | 142,799 shares |
| Market Cap | $27.44M |
| Exchange | NCM |
Technical Analysis (NRSN)
Nexqual's technical model rates NRSN "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:31 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.84 (neutral) |
| vs SMA50 | Below (USD 0.79) |
| MACD | -0.01 (negative) |
Analyst Ratings (NRSN)
Wall Street analysts rate NRSN "None" based on 3 analysts, with a mean price target of USD 6.5 (range USD 3–9), per Nexqual as of June 10, 2026 at 05:31 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 6.5 |
| High Target | USD 9 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (NRSN)
Source: Nexqual, June 10, 2026 at 05:31 UTC.
Financials & Fundamentals (NRSN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -2174.98% |
| Current Ratio | 0.31 |
| Total Cash | $166,000 |
| Total Debt | $170,000 |
| Free Cash Flow | $-3.87M |
Source: Nexqual, June 10, 2026 at 05:31 UTC.
Financial Health Score (NRSN)
Nexqual rates NRSN's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:31 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $166K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$8M |
| Efficiency | Critical — ROE -2175%, ROA -247.3% |
Ownership (NRSN)
| Insider Ownership | +32.30% |
|---|---|
| Institutional Ownership | +1.07% |
| Shares Outstanding | 36.10M |
| Float | 24.95M |
| Short % of Float | +1.32% |
Source: Nexqual, June 10, 2026 at 05:31 UTC.
Leadership (NRSN)
NRSN is led by Alon Ben-Noon (age 46), Co-Founder, CEO & Director, per Nexqual as of June 10, 2026 at 05:31 UTC.
| Co-Founder, CEO & Director | Alon Ben-Noon (age 46) |
|---|---|
| Chief Financial Officer | Or Eisenberg (age 44) |
| Chief Technology Officer | Niva Russek-Blum (age 46) |
Major Backers & Investors (NRSN)
Notable institutional backers of NRSN include Yorkville Advisors Global, LP, UBS Group AG, Independent Advisor Alliance, according to Nexqual as of June 10, 2026 at 05:31 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Yorkville Advisors Global, LP | 0.24% |
| UBS Group AG | 0.15% |
| Independent Advisor Alliance | 0.15% |
| Two Sigma Investments, LP | 0.14% |
| Meitav Investment House Ltd. | 0.12% |
Source: Nexqual, June 10, 2026 at 05:31 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| REVB | Revelation Biosciences, Inc. | USD 1.04 | ▲ 5.05% |
| IMMX | Immix Biopharma, Inc. | USD 8.01 | ▲ 1.01% |
| QNRX | Quoin Pharmaceuticals, Ltd. | USD 4.95 | ▲ 10.24% |
| BTTX | Better Therapeutics, Inc. | USD 0 | ▲ 0% |
| LIXT | Lixte Biotechnology Holdings, I | USD 6.87 | ▼ 1.86% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:31 UTC. This page is informational and not investment advice.